19 Jun
  • By L Fera
  • Cause in

Capricor Therapeutics Research Update for Duchenne

Capricor Therapeutics and CureDuchenne hosted a webinar on June 19, 2015. The presentation discussed the HOPE-DUCHENNE Trial. The U.S. Food and Drug Administration has cleared Capricor’s Investigational New Drug Application for the clinical development of CAP-1002 for the treatment of patients with Duchenne muscular dystrophy.

READ MORE
21 Jan
  • By L Fera
  • Cause in

Help Advance Research to Treat Heart Disease Associated with Duchenne

CureDuchenne and Capricor hosted a webinar on January 21, 2015 to discuss this promising research that addresses heart issues associated with Duchenne. Click here to watch the recording of the webinar. You’ll be prompted to enter your name and email address to view the recording.

READ MORE
21 Nov
  • By L Fera
  • Cause in

A New Duplication Exon 2 Mouse Model:A Tool for Studies of Duplication Skipping for Duchenne

CureDuchenne was pleased to host the “New Duplication Exon 2 Mouse Model: A Tool for Studies of Duplication Skipping for Duchenne” a webinar with Dr. Kevin Flanigan on November 21, 2013. The webinar was an opportunity for parents to learn about the duplication mutation research and an exciting exon skipping method using AAV delivery with U7 from Dr. Kevin Flanigan at Nationwide Children’s Hospital. CureDuchenne has provided the lead funding for Dr. Flanigan’s duplication research.

READ MORE
13 Sep
  • By L Fera
  • Cause in

Drug Development and Clinical Trial Participation Webinar

CureDuchenne was pleased to host the “Drug Development and Clinical Trial Participation – A Webinar for the Rare Disease Community” on Friday, September 13, 2013. The webinar was an opportunity for parents to learn about the drug development process – from the pre-clinical phase to the clinical phase to the post approval phase and the regulatory process guiding these phases – from industry experts.

READ MORE
20 Feb
  • By L Fera
  • Cause in

February 2013 FDA Webinar

CureDuchenne was honored to host a webinar on February 20, 2013, in collaboration with PPMD and MDA, to discuss accelerated approval for drugs for rare diseases. Dr. Robert Temple, director of the Office of Medical Policy of FDA’s Center for Drug Evaluation and Research, presented detailed information on the different options available to speed the […]

READ MORE